Gallant Therapeutics is a clinical-stage biotechnology company setting a new standard in animal health by delivering a pipeline of off-the-shelf stem cell therapies that target the root cause of major diseases in pets. Gallant is led by industry pioneers in veterinary regenerative medicine with deep expertise in development, manufacturing and early commercialization.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/24 | $15,000,000 | Series A |
Bold Capital Digitalis Ventures Hill Creek Partners | undisclosed |
